Phase 2 study of AU-011 for primary choroidal melanoma underway
The first patient has been dosed in a phase 2 clinical trial investigating safety and efficacy of suprachoroidal administration of AU-011 as a potential treatment for primary choroidal melanoma, according to a press release.
Aura Biosciences is the licensing partner of Clearside Biomedical for the development of AU-011 for the treatment of primary choroidal melanoma. Aura is using Clearside’s SCS microinjector to deliver the treatment, the release said.
AU-011 passed the safety review for the first dose escalation cohort, which noted no adverse events.
“With this trial initiation, we are on track to have three product candidates delivered via our SCS microinjector in four clinical trials this year,” Thomas A. Ciulla, MD, MBA, chief medical officer and chief development officer of Clearside, said in the release.